+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12896(FLT4 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12896(FLT4 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The FLT4 antibody targets the Fms-related tyrosine kinase 4 (FLT4), also known as vascular endothelial growth factor receptor 3 (VEGFR-3). FLT4 is a transmembrane receptor tyrosine kinase encoded by the *FLT4* gene, primarily expressed in lymphatic endothelial cells. It plays a critical role in regulating lymphangiogenesis (formation of lymphatic vessels) by binding to its ligands, VEGF-C and VEGF-D, which activate downstream signaling pathways like PI3K/AKT and MAPK, promoting cell proliferation, survival, and migration. Dysregulation of FLT4 is linked to pathologies such as lymphedema, tumor metastasis (via lymphatic spread), and inflammatory diseases.

FLT4 antibodies are essential tools in research and diagnostics. They enable detection of FLT4 expression via techniques like immunohistochemistry, flow cytometry, and Western blotting, aiding in studies of lymphatic system development and disease mechanisms. Monoclonal FLT4 antibodies have also been explored therapeutically to inhibit lymphangiogenesis in cancer, potentially reducing metastatic risk. For example, some antibodies block ligand-receptor interactions or receptor dimerization, suppressing pro-lymphangiogenic signaling. While clinical applications remain investigational, FLT4 antibodies are pivotal in understanding lymphatic biology and developing targeted therapies for conditions involving abnormal lymphatic growth or function. Their specificity and versatility make them valuable in both basic research and translational medicine.